Although full data is not available, two studies using the pill and an injectible version of the same drug as painkillers for patients undergoing open-heart surgery have now shown it raises the risk of new heart attacks.

FORBES: Can Vioxx Rivals Take The Pressure?

Pfizer 's (nyse: PFE - news - people ) Bextra, which increased the risk of heart attack and stroke in patients undergoing open heart surgery, and Arcoxia, Merck's (nyse: MRK - news - people ) still experimental follow-up to Vioxx, are the focus of a great deal of concern.

FORBES: Can Vioxx Rivals Take The Pressure?